Gilead Ramps Up For Ambrisentan; Calls For 75 To 100 Sales Reps

Company plans to go toe-to-toe with PAH competitors, CEO tells JP Morgan Healthcare Conference.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet